# A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

> **NCT02852655** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 60 (actual)

## Conditions studied

- Brain Cancer

## Interventions

- **DRUG:** MK-3475

## Key facts

- **NCT ID:** NCT02852655
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-09-21
- **Primary completion:** 2022-06-02
- **Final completion:** 2026-07-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02852655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02852655, "A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT02852655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*